Cryptosporidiosis: Transmission, Symptoms, Risks, and Treatment

What is Cryptosporidiosis?

Cryptosporidium is a microscopic, obligate intracellular parasite belonging to the phylum Apicomplexa. This taxonomic group also includes the malaria parasite (Plasmodium) and Toxoplasma gondii. The disease responsible for a severe diarrheal illness in children, known as cryptosporidiosis, is a significant global health problem.

• Cryptosporidiosis is the second most common cause of moderate-to-severe diarrheal illness in children under two years of age worldwide (after rotavirus in unvaccinated populations).
• Cryptosporidiosis is an important cause of childhood mortality in low- and middle-income countries, particularly in sub-Saharan Africa and South Asia.
• Cryptosporidiosis is likely significantly underdiagnosed globally. Routine stool analysis does not detect Cryptosporidium unless specifically requested, and many infections in healthy individuals resolve without any medical encounter.

The parasite is transmitted primarily through contaminated water, and it is remarkable for its extraordinary environmental resilience. Cryptosporidium oocysts (the infectious form) are highly resistant to standard chlorine-based water disinfection at routine concentrations, making them a persistent challenge for water treatment systems worldwide.

Clinical Spectrum

The clinical impact of Cryptosporidium infection is heavily determined by the immune status of the host:

• Immunocompetent individuals (with a healthy immune system): The infection is typically self-limiting. It causes profuse watery diarrhea lasting 7–14 days, then resolves spontaneously without specific treatment.
• Immunocompromised individuals: The infection can become severe, protracted, and potentially life-threatening. In HIV-positive individuals with low CD4+ counts, in transplant recipients, and in patients with primary immunodeficiency, cryptosporidiosis can persist for months or years and cause serious malnutrition, wasting, and biliary complications.

---

Transmission and Contagion

The Causative Organism

Cryptosporidiosis is caused by species of Cryptosporidium, a genus of apicomplexan protozoa. More than 40 species have been identified, of which at least 20 have been reported to infect humans. However, the vast majority of human disease is caused by two species:

• Cryptosporidium hominis: The dominant species causing human cryptosporidiosis in most parts of the world, adapted to human-to-human transmission.
• Cryptosporidium parvum: Primarily a zoonotic pathogen, it infects both humans and domestic animals, particularly cattle. This parasite is responsible for a significant proportion of human infections, especially in agricultural settings.

The organism has a complex life cycle that is completed entirely within a single host. After ingestion of oocysts (the environmentally resistant, infectious form), the parasite undergoes both asexual and sexual reproductive stages in the intestinal epithelium, ultimately producing new oocysts that are shed into the environment through the feces of infected individuals.

The Route of Transmission: Fecal-Oral

Transmission is unambiguously fecal-oral, i.e. the parasite must be ingested to cause infection. This can occur through multiple pathways:

Contaminated Water

Water is the most epidemiologically important vehicle for Cryptosporidium transmission, responsible for the majority of recognized outbreaks. The organism can contaminate:

• Drinking water: Municipal water supplies can become contaminated through agricultural runoff, sewage infiltration, or failure of filtration systems. The Milwaukee 1993 outbreak, the largest documented waterborne disease outbreak in US history, occurred when Cryptosporidium bypassed a water treatment plant serving the city.
• Recreational water: Swimming pools, water parks, splash pads, hot tubs, lakes, rivers, and ponds are all recognized transmission environments. Even a chlorinated swimming pool can be contaminated because Cryptosporidium oocysts are highly resistant to chlorine at concentrations used in recreational pools.
• Agricultural water: Water used to irrigate crops can carry Cryptosporidium from animal or human fecal contamination.

The critical characteristic of Cryptosporidium that makes water treatment so challenging: Standard chlorination at concentrations used in recreational pools and many municipal treatment systems does not effectively inactivate Cryptosporidium oocysts. Effective water treatment requires either UV irradiation, ozone treatment, or filtration to adequately reduce the oocyst burden.

Contaminated Food

Cryptosporidium can contaminate a wide range of food products:

• Fresh produce (salads, herbs, vegetables) irrigated with contaminated water or handled by infected food workers
• Raw or undercooked meat
• Unpasteurized milk or fruit juices
• Shellfish harvested from contaminated water

Direct Contact with Infected Individuals or Animals

Cryptosporidium spreads very efficiently through direct contact because:

• The infectious dose is very low. In fact, ingestion of as few as 10 oocysts can cause infection in a healthy adult.
• Infected individuals shed massive numbers of oocysts; during acute infection, this can reach up to 10 billion per gram of stool.

Direct transmission routes include:

• Person-to-person: Contact with an infected individual’s feces, particularly in childcare settings (such as diaper changing without adequate hand hygiene), healthcare settings, and households.
• Animal-to-person (zoonotic): C. parvum is a major zoonotic pathogen. Direct contact with infected animals, particularly young calves, lambs, goats, and other ruminants, or their environments is a recognized transmission route. Reported source animals include:
  • Cattle (particularly calves)
  • Sheep and goats
  • Rodents
  • Dogs and cats
  • Birds
  • Fish
  • Reptiles

Environmental Persistence

A critical feature enabling large outbreaks is the extraordinary environmental durability of Cryptosporidium oocysts:

• Oocysts can survive for months in moist soil or water. This holds true even under conditions of temperature extremes, including both heat and cold.
• They resist UV radiation, desiccation, and most chemical disinfectants at standard concentrations.
• In refrigerated water, they can survive for over a year.
• This persistence allows sustained environmental contamination and supports the maintenance of epidemic foci in settings such as:
  • Hospitals: Healthcare-associated cryptosporidiosis outbreaks have been documented.
  • Childcare centers and nurseries: Where diaper-changing creates contaminated environments and hand hygiene is difficult to maintain consistently.
  • Family households and community groups sharing food and water.
  • Swimming pools and recreational water facilities.
  • Agricultural environments with infected livestock.

Risk Factors

While cryptosporidiosis can affect anyone who ingests Cryptosporidium oocysts, certain populations face substantially higher risk of both infection and severe disease:

Children, particularly those between the ages of 1 and 5 years, are among the most commonly affected for several reasons:

• More likely to engage in behaviors that facilitate fecal-oral transmission (hand-to-mouth behavior, diaper changes, crawling on contaminated surfaces).
• Spending time in childcare settings where outbreaks occur.
• Immune system still maturing, with less robust adaptive immunity.

Elderly individuals: Age-related immune senescence and increased likelihood of co-morbidities reduce the ability to contain infection.

Travelers (particularly to low- and middle-income countries): Exposure to contaminated water or food in settings with inadequate sanitation infrastructure.

Swimmers and regular users of recreational water facilities should be aware that multiple studies have linked pool use, particularly in hot tubs and indoor pools, to cryptosporidiosis outbreaks.

Agricultural workers and rural populations in contact with livestock: Particularly relevant for C. parvum zoonotic transmission.

Immunocompromised individuals face both higher infection risk and dramatically worse outcomes:

• HIV/AIDS patients: The risk of cryptosporidiosis increases sharply when CD4+ T lymphocyte counts fall below 200 cells/µL. In HIV-positive individuals with advanced immunosuppression (CD4 <50 cells/µL), cryptosporidiosis can be devastating and potentially fatal. HIV-positive patients also have higher rates of biliary and pulmonary involvement.
• Transplant recipients: Both solid organ transplant recipients (on calcineurin inhibitors and corticosteroids) and hematopoietic stem cell transplant recipients have high rates of cryptosporidiosis, and infection can be protracted and severe
• Patients receiving cancer chemotherapy: Chemotherapy-induced immunosuppression creates vulnerability during treatment
• Individuals on immunosuppressive medications: Including high-dose corticosteroids, anti-TNF biologics, and other immunomodulatory therapies
• Primary immunodeficiency patients: Particularly those with IgA deficiency, combined variable immunodeficiency (CVID), and other conditions affecting mucosal immunity or T cell function

---

Incubation Period

Following ingestion of infectious oocysts, the incubation period (the time between exposure and the onset of symptoms) ranges from 2 to 10 days, with a mean of approximately 7 days. This relatively short and consistent incubation period has epidemiological utility: it helps trace the timing of the exposure event when outbreak investigations are conducted.

The incubation period may vary slightly depending on:

• The number of oocysts ingested (the infectious dose)
• The immune status of the host
• The specific Cryptosporidium species involved

---

Symptoms

The Mechanism of Disease

The symptoms of cryptosporidiosis arise from three interconnected pathophysiological processes:

1. Inflammatory response: Cryptosporidium attaches to and invades the luminal surface of intestinal epithelial cells. The host immune system responds with an influx of inflammatory cells, such as lymphocytes, eosinophils, and neutrophils, into the intestinal mucosa. This process drives inflammation and mucosal damage.

2. Structural intestinal damage: Infection leads to:

   • Villous atrophy: Shortening and blunting of the intestinal villi. These finger-like projections normally increase the intestinal surface area available for absorption.
   • Increased epithelial permeability: The tight junctions between intestinal epithelial cells are disrupted, allowing luminal contents (bacteria, toxins) to pass between cells.
   • Epithelial cell death (apoptosis): Direct parasite-mediated cytotoxicity.

3. Malabsorption: The combined effect of villous atrophy and epithelial damage severely impairs the intestine’s ability to absorb fluids, electrolytes, and nutrients. This impairment explains the profuse watery diarrhea, as well as the resulting dehydration and malnutrition.

In Immunocompetent Individuals

The infection may occasionally be asymptomatic. This is especially true when the inoculum (the number of oocysts ingested) is small or when the host has robust immunity. In these cases, the parasite is cleared without the individual ever experiencing symptoms, and they may not even know they were infected.

When symptoms develop, the characteristic presentation is:

Profuse, watery diarrhea is the hallmark symptom. Characterized by:

• Large volumes of watery, non-bloody stool (the absence of blood is an important distinguishing feature from bacterial colitis).
• High frequency: multiple episodes per day.
• Associated with crampy abdominal discomfort.

The pattern is often cyclical: Many patients experience alternating periods of improvement and worsening over 1–2 weeks, rather than a linear progression to resolution. This cyclic pattern reflects the asexual reproductive cycle of the parasite and the production of auto-infective thin-walled oocysts that can immediately reinfect the intestinal epithelium without leaving the host.

Additional symptoms commonly include:

• Fever: Low-grade fever is common, particularly in children. High fever is less typical and should prompt consideration of bacterial superinfection or alternative diagnoses.
• Nausea and vomiting: More prominent in children than adults; vomiting contributes significantly to fluid and electrolyte loss
• Abdominal pain: Crampy, diffuse lower abdominal pain associated with diarrhea episodes
• Fatigue and malaise: From fluid loss and metabolic demand of fighting the infection
• Loss of appetite (anorexia): Contributing to nutritional depletion

Outcome in immunocompetent individuals: In the majority of cases, diarrhea resolves spontaneously within 7–14 days without specific anti-parasitic treatment. This self-limiting course is the basis for the conservative management approach in healthy patients.

In Immunocompromised Individuals

The clinical presentation in immunocompromised patients is typically substantially more severe and follows a different natural history:

• Higher stool frequency and volume: The diarrhea may be profuse, with stool output reaching several liters per day in the most severe cases.
• Prolonged duration: Without immune reconstitution, the infection does not self-resolve.
• Wasting and severe malnutrition: The combination of profuse diarrheal losses, malabsorption, and poor oral intake causes rapid, severe nutritional deterioration.
• Systemic dissemination: Unlike in immunocompetent hosts, Cryptosporidium can spread beyond the intestine in profoundly immunosuppressed patients, leading to biliary and pulmonary involvement (see Complications).

---

Complications

The most serious complications of cryptosporidiosis occur almost exclusively in immunocompromised patients. However, severe dehydration can still be dangerous for any age group, particularly young children.

Chronic and Persistent Infection

In immunocompromised patients, particularly those with HIV/AIDS and uncontrolled viral replication (high viral load and low CD4 count), chronic cryptosporidiosis is a recognized and devastating complication.

• The diarrhea and related symptoms can persist for months or even years in the absence of immune reconstitution.
• Chronic diarrheal disease is the primary driver of the associated complications:
  • Malnutrition and weight loss: The intestinal malabsorption combined with anorexia and increased metabolic demand of chronic infection causes severe wasting.
  • Growth failure in children: Chronic malnutrition during critical developmental windows impairs both physical growth and cognitive development.
  • Cognitive deterioration: Chronic malnutrition and the metabolic burden of persistent infection can cause lasting neurodevelopmental impairment, particularly in young children.

Biliary Involvement

Cryptosporidium can invade the biliary tract, which includes the bile ducts draining the liver, in immunocompromised patients. This invasion produces cryptosporidial cholangiopathy, also called AIDS cholangiopathy when it occurs in HIV-positive patients.

• Infection of the bile duct epithelium causes inflammation, stricturing (narrowing), and dysfunction.
• Clinically presents with right upper quadrant pain, jaundice, elevated liver enzymes (particularly alkaline phosphatase and gamma-GT), and signs of biliary obstruction.
• Diagnosis is confirmed by imaging, such as MRCP or endoscopic retrograde cholangiopancreatography (ERCP), and by detecting the parasite in bile or duodenal fluid.
• Management is challenging. It requires both antifungal treatment and biliary drainage, and outcomes are poor without immune reconstitution.

Pulmonary Involvement

Respiratory cryptosporidiosis is rare but recognized in severely immunocompromised patients:

• Cryptosporidium can infect the epithelial cells of the respiratory tract (bronchi, trachea, and occasionally the lung parenchyma)
• Presents with cough, dyspnea, and radiological changes
• Diagnosis requires bronchoscopy with bronchoalveolar lavage and specific staining

Mortality

Cryptosporidiosis carries clinically meaningful mortality risk in two populations:

1. Young children in low- and middle-income countries: Where access to rehydration therapy and nutritional support is limited, severe dehydrating diarrhea in infancy can be fatal. Population studies have identified cryptosporidiosis as an independent risk factor for childhood mortality in high-burden regions.

2. Severely immunocompromised adults: Particularly HIV-positive patients with CD4 counts below 50 cells/µL who do not have access to antiretroviral therapy.

---

Diagnosis

Clinical Suspicion

The diagnosis of cryptosporidiosis should be considered in any patient presenting with:

• Profuse, watery, non-bloody diarrhea lasting more than a few days
• Recent exposure to potentially contaminated water (swimming pools, lakes, travel to endemic areas)
• Close contact with young children in diapers
• Exposure to farm animals
• Any degree of immunocompromise

Standard microbiological stool cultures ordered for diarrhea will not identify Cryptosporidium. To detect this parasite, the laboratory must be specifically instructed to perform the test.

Stool Testing: The Foundation of Diagnosis

Detection of Cryptosporidium in stool specimens is the cornerstone of laboratory diagnosis. Because the parasite is shed intermittently, rather than continuously, testing three stool samples collected on separate days is recommended to maximize sensitivity.

Microscopic Methods

Modified Ziehl-Neelsen acid-fast staining (and modified Kinyoun stain): The most widely used traditional staining method. Cryptosporidium oocysts stain bright pink or red against a blue or green background. This appearance is highly distinctive when present. Sensitivity is 60–90% depending on the stool concentration method used prior to staining.

Direct fluorescent antibody (DFA) assay: Uses fluorescently labelled antibodies specific for Cryptosporidium (and frequently also Giardia) to identify oocysts under fluorescence microscopy. Superior sensitivity to acid-fast staining.

Modified safranin stain: An alternative chromogenic method.

Antigen Detection (Immunoassay)

Enzyme immunoassay (EIA) / ELISA: Detects Cryptosporidium antigens in stool. Good sensitivity (90–95%) and specificity. Many commercial kits are available. Can be performed in most clinical laboratories.

Lateral flow immunochromatographic assay (rapid test): This method follows a similar principle to a home pregnancy test. It produces a visual line result within minutes. Convenient for rapid diagnosis in clinical or field settings. Many kits test simultaneously for Cryptosporidium and Giardia.

Molecular Methods

Polymerase chain reaction (PCR): Detection and amplification of Cryptosporidium DNA from stool. Currently, the most sensitive diagnostic method available can detect very low oocyst concentrations. Additionally allows:

• Species identification: Distinguishing C. hominis from C. parvum and other epidemiologically and clinically important species.
• Genotyping: Further molecular characterization for outbreak investigations.

PCR is increasingly available in clinical microbiology laboratories and is recommended for immunocompromised patients and when other methods are negative despite strong clinical suspicion.

Next-generation sequencing (metagenomic sequencing): Emerging technology that can identify Cryptosporidium alongside all other pathogens present in a stool sample at the same time. It is likely to become more widely available in the coming years.

Serological Testing

Blood-based serological tests (detecting antibodies against Cryptosporidium) are available but are primarily used for epidemiological research, for example, to estimate the prevalence of past infection in populations, rather than for individual clinical diagnosis. This is because:

• Antibodies persist after infection resolves and cannot reliably distinguish active from past infection
• Sensitivity and specificity are insufficient for clinical diagnostic use

Differential Diagnosis

Cryptosporidiosis must be distinguished from other causes of watery diarrhea. The most important conditions in the differential include other intestinal infections:

In clinical practice, multiple stool pathogens are often sought simultaneously using multiplex PCR panels (GI panels) that detect bacterial, viral, and parasitic causes of diarrhea in a single test.

Investigation in Immunocompromised Patients

In immunocompromised patients with cryptosporidiosis, additional investigations may be warranted:

• Liver function tests and abdominal imaging (ultrasound, MRCP): To assess for biliary involvement.
• Chest imaging and bronchoscopy: If respiratory symptoms are present.
• CD4+ count and HIV viral load: In HIV-positive patients, these are critical for determining treatment strategy.
• Ophthalmological examination: In severely immunocompromised HIV-positive patients, other opportunistic infections may coexist.

---

Treatment

Immunocompetent Patients: Supportive Care First

In patients with a healthy immune system, cryptosporidiosis is self-limiting and will resolve spontaneously in 7–14 days in most cases. The cornerstone of management is supportive care:

Rehydration

Oral rehydration therapy (ORT) is the most critical intervention in cryptosporidiosis, both in mild-to-moderate disease and as an adjunct to any pharmacological treatment:

• Replace fluid and electrolyte losses from diarrhea and vomiting.
• Use oral rehydration solution (ORS), such as commercially available sachets or home-prepared solutions containing appropriate glucose and electrolyte concentrations. Plain water alone is insufficient for severe diarrhea as it does not replace electrolyte losses.
• In severe dehydration, particularly in young children and the elderly, intravenous (IV) fluid administration may be required.

Signs of dehydration requiring urgent medical attention:

• Decreased urination (dry diapers in infants).
• Sunken eyes, dry mouth and skin.
• Lethargy or reduced activity.
• No tears when crying (in infants).
• In adults: dizziness, confusion, rapid heart rate.

Nutritional Support

Maintaining adequate nutrition is important for immune function and recovery:

• Continue eating. Bland, easily digestible foods are typically better tolerated during acute illness.
• Avoid foods that worsen diarrhea (high-fat foods, caffeine, high-fiber foods, dairy products during acute illness).
• In children, the WHO recommends continuing age-appropriate feeding, including breastfeeding, throughout acute diarrheal illness. Early refeeding improves recovery and reduces nutritional deficits.

Antiparasitic Drug Therapy

Nitazoxanide

Nitazoxanide is the only drug specifically approved by the FDA (US Food and Drug Administration) for the treatment of cryptosporidiosis. It is a thiazolide antiparasitic agent that inhibits Cryptosporidium and a range of other intestinal parasites.

• Approved doses:
  • Children 1–3 years: 100 mg twice daily for 3 days.
  • Children 4–11 years: 200 mg twice daily for 3 days.
  • Adults and children ≥12 years: 500 mg twice daily for 3 days.
• Efficacy: Clinical trials demonstrate significant reduction in diarrhea duration and symptom severity in immunocompetent children and adults. Results in immunocompromised patients are substantially less consistent.
• Availability: Available in the United States and several other countries.

Alternative Pharmacological Agents

When nitazoxanide is unavailable or contraindicated, alternatives include:

• Paromomycin: An aminoglycoside antibiotic with anti-parasitic activity against Cryptosporidium. Shows some efficacy in immunocompetent patients; results are inconsistent in immunocompromised individuals. Used at 25–35 mg/kg/day in divided doses.

• Azithromycin: A macrolide antibiotic with activity against Cryptosporidium. Sometimes used in combination with paromomycin in immunocompromised patients. Typical dose: 500–600 mg/day in adults.

• Combination therapy: Paromomycin + azithromycin may provide additive benefit in immunocompromised patients who fail monotherapy.

A critical limitation: In immunocompromised patients, particularly those with HIV/AIDS, antiparasitic drug therapy alone is rarely effective in achieving lasting cure. Without restoration of immune function, the parasite persists and the drugs fail to clear the infection. This underscores the paramount importance of immune reconstitution (see below).

Management in Immunocompromised Patients

The treatment of cryptosporidiosis in immunocompromised individuals is fundamentally different from management in healthy hosts, because:

1. The infection does not self-resolve
2. Available antiparasitic drugs have limited efficacy without immune function
3. Immune reconstitution is the single most impactful therapeutic intervention

HIV-Positive Patients

The most important intervention in HIV-positive patients with cryptosporidiosis is optimizing antiretroviral therapy (ART):

• Initiation of effective ART (if not already on treatment) or optimization of the ART regimen (if treatment failure has occurred).
• Successful ART reduces HIV viral load, allowing CD4+ T cell counts to recover.
• As CD4 counts rise above 100-200 cells/µL, cryptosporidiosis typically resolves, even without specific antiparasitic treatment.
• In patients who cannot tolerate or access ART, outcomes are substantially worse.

Antiparasitic therapy (nitazoxanide where available, paromomycin, azithromycin) should be used alongside ART optimization as supportive treatment.

Transplant Recipients and Other Immunosuppressed Patients

• Dose reduction of immunosuppressive medications (where clinically safe and compatible with preventing organ rejection or controlling the underlying disease) can allow partial immune reconstitution sufficient to control the infection
• Antiparasitic agents are used as supportive treatment
• Multidisciplinary management involving the transplant team, infectious disease specialists, and gastroenterologists is essential

Symptomatic and Supportive Measures

Regardless of immune status, supportive measures are essential:

• Aggressive rehydration: IV fluids are often required in severe cases, targeting correction of fluid deficits and ongoing replacement of diarrheal losses.
• Nutritional support: Enteral nutrition (via nasogastric tube) or parenteral nutrition may be required in patients who cannot maintain oral intake. This is especially important in children, as malnutrition can cause lasting developmental harm.
• Antimotility agents (loperamide): Can reduce stool frequency and improve quality of life in symptomatic patients, but should be used cautiously and avoided in children under 2 years. They do not treat the infection.
• Octreotide: A somatostatin analogue that reduces secretory diarrhea through multiple mechanisms. It is sometimes used in severe, refractory cryptosporidial diarrhea in immunocompromised patients as a palliative measure.

Prevention at the Individual Level

While a dedicated prevention section could be a separate article, the key individual-level measures include:

• Water safety: Drink treated, filtered, or boiled water when traveling or in settings with uncertain water quality. For immunocompromised individuals at home: use NSF-certified 1-micron absolute pore filters, or drink bottled water from reliable sources. Avoid swallowing water during recreational swimming.
• Hand hygiene: Thorough handwashing with soap and water after using the toilet, changing diapers, handling animals, and before food preparation. Alcohol-based hand sanitizers are not effective against Cryptosporidium oocysts; instead, soap and water mechanical washing is required.
• Food safety: Wash produce thoroughly; avoid raw or undercooked foods in high-risk settings; avoid unpasteurized milk and juices.
• Swimming precautions: Do not swim when experiencing diarrhea (and for 2 weeks after recovery); avoid swallowing pool water; shower before entering pools; take children for regular toilet breaks rather than relying on swim diapers.
• Animal contact: Wash hands after contact with animals, particularly farm animals and their environments; children should be closely supervised during petting zoo visits.
• For immunocompromised individuals: Avoid contact with young animals (particularly calves, lambs), avoid recreational water exposures, use boiled or filtered water, and discuss preventive strategies with their physician.

---

Sources and Bibliography

• Janssen B, Snowden J. “Cryptosporidiosis”. StatPearls. NCBI Bookshelf.
• Centers for Disease Control and Prevention (CDC): Cryptosporidium
• European Centre for Disease Prevention and Control (ECDC): Cryptosporidiosis
• Kotloff KL, et al. “Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS)”. Lancet. 2013;382(9888):209–222.
• Checkley W, et al. “A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium”. Lancet Infectious Diseases. 2015;15(1):85–94.
• Rossignol JF. “Cryptosporidium and Giardia: treatment options and prospects for new drugs”. Experimental Parasitology. 2010;124(1):45–53.
• Mor SM, Tzipori S. “Cryptosporidiosis in children in sub-Saharan Africa: a lingering challenge”. Clinical Infectious Diseases. 2008;47(7):915–921.
• Hunter PR, Nichols G. “Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients”. Clinical Microbiology Reviews. 2002;15(1):145–154.
• Abubakar I, et al. “Diagnosis of Cryptosporidiosis: a systematic review”. Journal of Medical Microbiology. 2007;56(Pt 5):573–582.
• World Health Organization (WHO). “The treatment of diarrhoea: a manual for physicians and other senior health workers”. 2005.